The nation of Zimbabwe has rejected a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on sensitive data.
The decision came to light following a official document dated December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
A government representative has since clarified that the United States was requesting health data for research and commercial gain but refused to guarantee the benefits from future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more negotiations to find a deal suitable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Background
This development comes after a comparable case in neighbouring Kenya, where a court blocked a similar deal with the US following legal challenges were raised about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
Based on reports, 16 nations in Africa have to date signed these new agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our nation would provide the raw materials for medical research without any certainty that the final treatments would be available to our population should a new pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of bilateral health agreements were disrupting structures previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further dialogue with our US partners on how future collaboration might be arranged in a way that honours the independence and interests of each country."
Health Experts Response
A leading public health body said it acknowledged the official position, but recommended that negotiations must proceed since a large portion of the country's Aids initiatives relied on external financing.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," the group added.
This impasse emphasises the complex debate between receiving vital international aid and safeguarding local interests in an ever more data-driven world.